Journal article
Preclinical target validation for non-addictive therapeutics development for pain
Expert opinion on therapeutic targets, v 26(9), pp 811-822
02 Sep 2022
PMID: 36424892
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Introduction: The Helping to End Addiction Long-term(SM) Initiative supports a wide range of programs to develop new or improved prevention and opioid addiction treatment strategies. An essential component of this effort is to accelerate development of non-opioid pain therapeutics. In all fields of medicine, therapeutics development is an arduous process and late-stage translational efforts such as clinical trials to validate targets are particularly complex and costly. While there are plentiful novel targets for pain treatment, successful clinical validation is rare. It is therefore crucial to develop processes whereby therapeutic targets can be reasonably "de-risked' prior to substantial late-stage validation efforts. Such rigorous validation of novel therapeutic targets in the preclinical space will give potential private sector partners the confidence to pursue clinical validation of promising therapeutic concepts and compounds. Areas covered: In 2020, the National Institutes of Health (NIH) held the Target Validation for Non- Addictive Therapeutics Development for Pain workshop to gather insights from key opinion leaders in academia, industry, and venture-financing. Expert opinion: The result was a roadmap for pain target validation focusing on three modalities: 1) human evidence; 2) assay development in vitro; 3) assay development in vivo
Metrics
Details
- Title
- Preclinical target validation for non-addictive therapeutics development for pain
- Creators
- Richard Hargreaves - Bristol-Myers Squibb (United States)Karen Akinsanya - Schrodinger (United States)Seena K. Ajit - Drexel UniversityNeel T. Dhruv - National Institute of Neurological Disorders and StrokeJamie Driscoll - National Institute of Mental HealthPeter Farina - Westport InnovationsNarender Gavva - Drug Discovery Sciences, Takeda Pharmaceuticals, San Diego, California, United States.Marie Gill - National Institute of Neurological Disorders and StrokeAndrea Houghton - Merck & Co., Inc., Rahway, NJ, USA (United States)Smriti Iyengar - National Institute of Neurological Disorders and StrokeCarrie Jones - Vanderbilt UniversityAnnemieke Kavelaars - The University of Texas MD Anderson Cancer CenterAjamete Kaykas - Insitro, San Francisco, California, United States.Walter J. Koroshetz - National Institute of Neurological Disorders and StrokePascal Laeng - National Institute of Neurological Disorders and StrokeJennifer M. Laird - Eli Lilly and Company, Windlesham, United Kingdom of Great Britain and Northern Ireland.Donald C. Lo - National Center for Advancing Translational SciencesJohan Luthman - Lundbeck (Denmark)Gordon Munro - Horiba (Japan)Michael L. Oshinsky - National Institute of Neurological Disorders and StrokeG. Sitta Sittampalam - National Center for Advancing Translational SciencesSarah A. Woller - National Institute of Neurological Disorders and StrokeAmir P. Tamiz - National Institute of Neurological Disorders and Stroke
- Publication Details
- Expert opinion on therapeutic targets, v 26(9), pp 811-822
- Publisher
- Taylor & Francis
- Number of pages
- 12
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine; Pharmacology and Physiology; Drexel University
- Web of Science ID
- WOS:000890826600004
- Scopus ID
- 2-s2.0-85142620000
- Other Identifier
- 991020099044104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Pharmacology & Pharmacy